191 related articles for article (PubMed ID: 22240794)
1. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
[TBL] [Abstract][Full Text] [Related]
3. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
Cella D; Michaelson MD; Bushmakin AG; Cappelleri JC; Charbonneau C; Kim ST; Li JZ; Motzer RJ
Br J Cancer; 2010 Feb; 102(4):658-64. PubMed ID: 20104222
[TBL] [Abstract][Full Text] [Related]
6. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Luo X; Cappelleri JC; Cella D; Li JZ; Charbonneau C; Kim ST; Chen I; Motzer RJ
Value Health; 2009 Jun; 12(4):580-6. PubMed ID: 19900256
[TBL] [Abstract][Full Text] [Related]
7. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
[TBL] [Abstract][Full Text] [Related]
8. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
Cella D; Choueiri TK; Hamilton M; Blum SI; Ivanescu C; Karu K; Ejzykowicz F; Motzer RJ
Oncologist; 2024 Jun; 29(6):511-518. PubMed ID: 38280218
[TBL] [Abstract][Full Text] [Related]
9. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
10. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
[TBL] [Abstract][Full Text] [Related]
11. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
13. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
Miyake H; Miyazaki A; Harada K; Fujisawa M
Med Oncol; 2014 Jun; 31(6):978. PubMed ID: 24793747
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Herrmann E; Gerss J; Bierer S; Köpke T; Bolenz C; Hertle L; Wülfing C
J Cancer Res Clin Oncol; 2009 Jan; 135(1):61-7. PubMed ID: 18592270
[TBL] [Abstract][Full Text] [Related]
15. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
Patil S; Figlin RA; Hutson TE; Michaelson MD; Negrier S; Kim ST; Huang X; Motzer RJ
Br J Cancer; 2012 May; 106(10):1587-90. PubMed ID: 22568998
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Castellano D; del Muro XG; Pérez-Gracia JL; González-Larriba JL; Abrio MV; Ruiz MA; Pardo A; Guzmán C; Cerezo SD; Grande E
Ann Oncol; 2009 Nov; 20(11):1803-12. PubMed ID: 19549706
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Rixe O; Oudard S; Negrier S; Szczylik C; Kim ST; Chen I; Bycott PW; Baum CM; Figlin RA
N Engl J Med; 2007 Jan; 356(2):115-24. PubMed ID: 17215529
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
20. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cella D; Davis MP; Négrier S; Figlin RA; Michaelson MD; Bushmakin AG; Cappelleri JC; Sandin R; Korytowsky B; Charbonneau C; Matczak E; Motzer RJ
Cancer; 2014 Jun; 120(12):1871-80. PubMed ID: 24634003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
